GFAP and Alexander disease: To further validate the zebrafish model of AxD, we investigated whether the antibiotic ceftriaxone (CEF), previously shown to decrease mutant GFAP aggregation in vitro [10] and to improve the clinical severity in an AxD patient [28], could also exert beneficial effects in our in vivo model.